非常规组织学类型前列腺癌在接受机器人根治性前列腺切除术的局限性病变中的肿瘤学与功能预后价值:一项国际多中心5年队列研究
该回顾性国际多中心队列纳入2016至2020年间接受机器人辅助根治性前列腺切除术的3935例局限性前列腺癌患者,比较筛状结构、导管腺癌和导管内癌与纯腺癌的肿瘤学及功能结局。中位随访2.8年,非常规组织学与更差的无生化复发生存、更高的辅助放疗接受率及1年勃起功能障碍风险相关,筛状结构还与更高的尿失禁风险相关。
要点
- 中位随访2.8年,非常规组织学组生化复发率和辅助放疗接受率高于纯腺癌组。
- 与纯腺癌相比,导管腺癌、导管内癌和筛状结构的5年无生化复发生存率显著更差。
- 非常规组织学使1年新发勃起功能障碍风险约翻倍,筛状结构还与尿失禁风险升高相关。
核心结论
- 在大队列中,非常规组织学的存在与机器人辅助根治性前列腺切除术后较差的短期至中期肿瘤学结局相关。
- 导管内癌独立预测更高的辅助放疗接受率。
- 术后1年随访时,非常规组织学患者发生勃起功能障碍的风险是纯腺癌的3倍;筛状结构与2倍的尿失禁率相关。
研究设计与样本
- 回顾性收集2016年至2020年间接受机器人辅助根治性前列腺切除术的局限性前列腺癌男性的大型国际队列数据。
- 共纳入3935例患者,中位随访2.8年。
- 主要结局为无生化复发生存、勃起功能和控尿功能;辅助放疗接受率为次要结局。
- 采用Kaplan-Meier生存分析和Cox回归分析。
主要发现
- 生化复发发生率:纯腺癌10.7% vs 导管内癌17%(p < 0.001)。
- 辅助放疗接受率:纯腺癌4.5% vs 导管腺癌6.3%(p = 0.003)vs 导管内癌11.2%(p < 0.001)。
- 5年无生化复发生存率:与纯腺癌相比,导管腺癌HR 1.67(95%CI 1.16-2.40;p = 0.005),导管内癌HR 5.22(95%CI 3.41-8.01;p < 0.001),筛状结构HR 3.45(95%CI 2.29-5.20;p < 0.001)。
- 1年新发勃起功能障碍风险:与纯腺癌(grade group 1-3)相比,导管腺癌HR 2.13(p < 0.001),导管内癌HR 2.14(p < 0.001),筛状结构HR 2.01(p = 0.011)。
- 尿失禁风险:筛状结构OR 1.97(p < 0.001);导管内癌或导管腺癌与尿失禁风险无显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏中心病理学复核。
- 随访时间相对较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The impact of prostate cancer of unconventional histology (UH) on oncological and functional outcomes after robot-assisted radical prostatectomy (RARP) and adjuvant radiotherapy (aRT) receipt is unclear. We compared the impact of cribriform pattern (CP), ductal adenocarcinoma (DAC), and intraductal carcinoma (IDC) in comparison to pure adenocarcinoma (AC) on short- to mid-term oncological and functional results and receipt of aRT after RARP. METHODS: We retrospectively collected data for a large international cohort of men with localized prostate cancer treated with RARP between 2016 and 2020. The primary outcomes were biochemical recurrence (BCR)-free survival, erectile and continence function. aRT receipt was a secondary outcome. Kaplan-Meier survival and Cox regression analyses were performed. KEY FINDINGS AND LIMITATIONS: A total of 3935 patients were included. At median follow-up of 2.8 yr, the rates for BCR incidence (AC 10.7% vs IDC 17%; p < 0.001) and aRT receipt (AC 4.5% vs DAC 6.3% [p = 0.003] vs IDC 11.2% [p < 0.001]) were higher with UH. The 5-yr BCR-free survival rate was significantly poorer for UH groups, with hazard ratios of 1.67 (95% confidence interval [CI] 1.16-2.40; p = 0.005) for DAC, 5.22 (95% CI 3.41-8.01; p < 0.001) for IDC, and 3.45 (95% CI 2.29-5.20; p < 0.001) for CP in comparison to AC. Logistic regression analysis revealed that the presence of UH doubled the risk of new-onset erectile dysfunction at 1 yr, in comparison to AC (grade group 1-3), with hazard ratios of 2.13 (p < 0.001) for DAC, 2.14 (p < 0.001) for IDC, and 2.01 (p = 0.011) for CP. Moreover, CP, but not IDC or DAC, was associated with a significantly higher risk of incontinence (odds ratio 1.97; p < 0.001). The study is limited by the lack of central histopathological review and relatively short follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: In a large cohort, UH presence was associated with worse short- to mid-term oncological outcomes after RARP. IDC independently predicted a higher rate of aRT receipt. At 1-yr follow-up after RP, patients with UH had three times higher risk of erectile dysfunction post RARP; CP was associated with a twofold higher incontinence rate. PATIENT SUMMARY: Among patients with prostate cancer who undergo robot-assisted surgery to remove the prostate, those with less common types of prostate cancer have worse results for cancer control, erection, and urinary continence and a higher probability of receiving additional radiotherapy after surgery.
引用
- Leung D, Castellani D, Nicoletti R, et al. The Oncological and Functional Prognostic Value of Unconventional Histology of Prostate Cancer in Localized Disease Treated with Robotic Radical Prostatectomy: An International Multicenter 5-Year Cohort Study. Eur Urol Oncol. 2024. PMID: 38185614. doi:10.1016/j.euo.2023.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。